Antibody sequence and structure analysis to evaluate, rank order, and engineer biotherapeutics.
Identify and engineer stable, manufacturable candidates before you invest in the lab.
Pursuing a poorly behaving antibody is one of the most expensive mistakes in drug discovery.
Sequence and structural filtering minimizes this risk.
Empirical validation proves the case for early stage developability optimization.
Evaluate antibody sequences across a wide range of developability attributes to rank order and select lead candidates.
Design and evaluate optimization variants and humanizations directly within the application workspace.
Interactive dashboards and visualizations for sequence alignment, diversity, structure mapping, and variant selection.